Dr Lowentritt on PSA Response and Time to Castration Resistance in mCSPC
April 29th 2023Benjamin H. Lowentritt, MD, FACS, discusses prostate-specific antigen response and time to castration resistance in patients with metastatic castration-sensitive prostate cancer started on apalutamide, enzalutamide, or abiraterone acetate.
Read More
Breakthroughs in Imaging Modalities for Prostate Cancer
March 3rd 2023Five expert panelists in prostate cancer consider how recent advances in imaging, particularly PSMA-PET, have impacted the field, and highlight guidelines that may aid clinicians in selecting amongst the available imaging modalities.
Read More